Therapeutic target and diagnostic marker for asthma and related conditions
OwnerFrancesca Levi-Schaffer, Ido Bachelet +2inventors
InventorsFrancesca Levi-Schaffer, Ido Bachelet, Ariel Munitz, Marc E. Rothenberg
Life of this patent
Estimating the term…
Abstract
CD48, a surface-marker molecule present in eosinophils, is disclosed herein as a key molecule in allergic conditions, particularly in allergic airway inflammations like asthma, allergy and nasal polyposis. CD48 is thus presented as a target molecule in the treatment of said conditions. In addition, diagnostic methods, and a kit for the diagnosis of allergic inflammatory conditions are described, based on the detection of CD48 expression.
Claims8
A method of treating an allergic condition, said method comprising administering a therapeutically effective amount of an anti-CD48 agent consisting of (i) an antibody which specifically binds to CD48 or (ii) a CD48 binding fragment of said antibody, which anti-CD48 agent blocks the CD48 stimulatory pathway, to a subject suffering from an allergic condition, wherein said allergic condition is an allergic inflammation selected from the group consisting of allergic airway inflammation, atopic dermatitis, conjunctivitis and intestinal allergy.
A method of inhibiting the activity and/or expression of CD48 in cells of a subject suffering from an allergic inflammation, said method comprising the step of in vivo contacting said cells with an effective amount of an anti-CD48 agent consisting of (i) an anti-CD48 antibody, (ii) a CD48 binding fragment of said antibody, or (iii) a combination thereof, wherein said allergic inflammation is selected from the group consisting of allergic airway inflammation, atopic dermatitis conjunctivitis and intestinal allergy.
A method of treating an allergic condition, said method comprising administering a therapeutically effective amount of an anti-CD48 agent consisting of (i) a neutralizing antibody, which specifically binds to CD48, or (ii) a CD48 binding fragment of said neutralizing antibody, which anti-CD48 agent blocks the CD48 stimulatory pathway, to a subject suffering from an allergic condition, wherein said allergic condition is an allergic inflammation selected from the group consisting of allergic airway inflammation, atopic dermatitis, conjunctivitis and intestinal allergy.
A method of inhibiting the activity and/or expression of CD48 in cells of a subject suffering from an allergic inflammation said method comprising the step of in vivo contacting said cells with an effective amount of an anti-CD48 agent consisting of (i) a neutralizing anti-CD48 antibody, (ii) a CD48 binding fragment of said neutralizing antibody, (iii) a combination thereof, or (iv) a composition comprising the same, wherein said allergic inflammation is selected from the group consisting of allergic airway inflammation, atopic dermatitis, conjunctivitis and intestinal allergy.
Dependencies are inferred from the claim text.